TC
MRTX

Telemus Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Telemus Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-40
Closed -$1K – 585
2017
Q4 		$1K Buy
+40
New +$621 ﹤0.01% 591

Other funds holding MRTX

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Putnam Investments
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Telemus Capital's MRTX Position: Q1 2018 in Review

Telemus Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2018, closing a stake of 40 shares — an estimated $1K sold.

Telemus Capital first reported a position in MRTX in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 81 funds tracked by Wall St. Rank hold MRTX as of Q1 2018.

  • Telemus Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Telemus Capital sold 40 Mirati Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $1K.
  • Telemus Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Telemus Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Telemus Capital's 13F filing for Q1 2018, filed 27 Apr 2018.